S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL
Steven Knapper,
Abin Thomas,
Sophie King,
Ian Thomas,
Amanda Gilkes,
Sarah Irwin,
Robert Sellar,
Simone Green,
Ulrik Malthe Overgaard,
Priyanka Mehta,
Mike Dennis,
Sylvie Freeman,
Nigel Russell
Affiliations
Steven Knapper
1 Division of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom
Abin Thomas
2 Centre for Trials Research, Cardiff University, Cardiff, United Kingdom
Sophie King
3 Centre for Trials Research, Cardiff University, Cardiff, United Kingdom
Ian Thomas
3 Centre for Trials Research, Cardiff University, Cardiff, United Kingdom
Amanda Gilkes
4 Division of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom
Sarah Irwin
5 Cardiff and Vale University Health Board, Cardiff, United Kingdom
Robert Sellar
6 University College Hospital, London, United Kingdom
Simone Green
7 Castle Hill Hospital, Hull, United Kingdom
Ulrik Malthe Overgaard
8 Rigshospitalet, Copenhagen, Denmark
Priyanka Mehta
9 University Hospital of Bristol and Weston NHS Trust, Bristol, United Kingdom
Mike Dennis
10 The Christie NHS Foundation Trust, Manchester, United Kingdom
Sylvie Freeman
11 Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
Nigel Russell
12 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
